AIDSWEEKLY Plus; Monday, September 6, 2004
Staff Medical Writers

"Enzyme-linked immunosorbent assay (ELISA) methods for quantification of HIV-1 p24 antigen have been relatively insensitive. In this report, we show data that indicate real-time immuno polymerase chain reaction (IPCR), a combination of the ELISA and PCR techniques, is more sensitive for HIV-1 p24 antigen detection than other currently reported methods."

"When derived from an IPCR standard curve, a dose response was observed from patient samples with known viral loads diluted within a 3-log range (1.68-6,514 viral RNA copies per milliliter). IPCR detected 42% (22/52) of patient samples that had fewer than 50 viral RNA copies per milliliter by reverse transcriptase-PCR," J.M. Barletta and colleagues reported.

"IPCR shows the potential to become the most analytically sensitive test available for determination of HIV-1 viral load by the detection of HIV-1 p24 antigen," scientists concluded.

Barletta and colleagues published their study in American Journal of Clinical Pathology (Lowering the detection limits of HIV-1 viral load using real-time Immuno-PCR for HIV-1 p24 antigen. Am J Clin Pathol. 2004 Jul;122(1):20-7.

For additional information, contact J.M. Barletta, University of Maryland, Department of Pathology, 725 W Lombard St., Baltimore, MD 21201 USA.

The publisher's contact information for the American Journal of Clinical Pathology is: American Society Clinical Pathology, 2100 W Harrison St., Chicago, IL 60612 USA.

The information in this article comes under the major subject areas of Immunology, AIDS/HIV, Diagnostics, Biotechnology, and Virology.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Barletta JM, Edelman DC, Constantine NT. "Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen", Am J Clin Pathol. 2004 Jul;122(1):20-7.

PubMED Related articles Search

040906
AW040903

Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.